STAMPEDE Trial and Patients With Non-Metastatic Prostate Cancer – Authors' Reply

The Lancet - United Kingdom
doi 10.1016/s0140-6736(16)31041-8
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Authors' Reply: Expanding Horizons in Metastatic Prostate Cancer Treatment

Nature Reviews Clinical Oncology
Oncology
2011English

Therapy for Prostate Cancer: The Authors Reply

Health Affairs
MedicineHealth Policy
2012English

The Drama of Prostate Cancer Diagnostics – Authors' Reply

The Lancet Oncology
Oncology
2017English

[ 177 Lu]-Psma-617 Radionuclide Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Re: Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

European Urology
Urology
2016English

Mp22-09 Association Between Androgen-Deprivation Therapy and Non-Prostate Cancer Mortality Among Men With Non-Metastatic Prostate Cancer

Journal of Urology
Urology
2018English

Phase II Trial of Dexverapamil and Epirubicin in Patients With Non-Responsive Metastatic Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

Phase 1 Trial of High-Dose Exogenous Testosterone in Patients With Castration-Resistant Metastatic Prostate Cancer

European Urology
Urology
2009English

Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy